B & T Capital Management DBA Alpha Capital Management Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)

B & T Capital Management DBA Alpha Capital Management purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,223 shares of the company's stock, valued at approximately $416,000.

A number of other large investors also recently bought and sold shares of the business. Cerity Partners LLC acquired a new position in CRISPR Therapeutics in the 1st quarter worth about $216,000. Leavell Investment Management Inc. acquired a new position in CRISPR Therapeutics in the 1st quarter worth about $340,000. Axxcess Wealth Management LLC raised its holdings in CRISPR Therapeutics by 4.0% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company's stock worth $351,000 after purchasing an additional 393 shares during the period. Envestnet Asset Management Inc. raised its holdings in CRISPR Therapeutics by 21.5% in the 1st quarter. Envestnet Asset Management Inc. now owns 68,058 shares of the company's stock worth $2,316,000 after purchasing an additional 12,025 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in CRISPR Therapeutics by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 77,702 shares of the company's stock worth $2,644,000 after purchasing an additional 1,133 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Transactions at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,932 shares of the stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the transaction, the insider owned 6,068 shares of the company's stock, valued at approximately $218,083.92. This represents a 39.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.30% of the company's stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock traded down $2.20 during trading hours on Friday, hitting $56.80. The company's stock had a trading volume of 2,883,963 shares, compared to its average volume of 1,945,294. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $63.68. The firm has a fifty day moving average of $42.52 and a 200-day moving average of $41.28. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of -12.57 and a beta of 1.82.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. During the same period last year, the business posted ($1.43) earnings per share. The business's quarterly revenue was up 71.6% compared to the same quarter last year. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Barclays dropped their price target on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research report on Friday, May 9th. Piper Sandler reiterated an "overweight" rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Needham & Company LLC reiterated a "buy" rating and set a $81.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday. Finally, Chardan Capital reiterated a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, June 26th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $71.75.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.